Medicare Part B Drug Reimbursement.
Monitor Appropriations and Continuing Resolutions.
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax. Monitor developments related to the Camp Tax Proposal. Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act, S.2260.
Monitor legislation as it relates to the renewable fuel standard.
Duration: March 15, 2013
to
June 1, 2014
General Issues: Health Issues , Budget/Appropriations , Taxation/Internal Revenue Code , Energy/Nuclear
Spending: about $380,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2014
FTI Government Affairs terminated an engagement in which they represented Biotechnology Industry Organization on July 17, 2014.
Original Filing: 300659232.xml
Lobbying Issues
Medicare Part B Drug Reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor Appropriations and Continuing Resolutions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax. Monitor developments related to the Camp Tax Proposal. Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act, S.2260.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislation as it relates to the renewable fuel standard.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, FTI Government Affairs lobbied for Biotechnology Industry Organization , earning $80,000. The report was filed on April 17, 2014.
Original Filing: 300640411.xml
Lobbying Issues
Medicare Part B Drug Reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor Appropriations and Continuing Resolutions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax. Monitor developments related to the Camp Tax Proposal. Expiring Provisions Improvement Reform and Efficiency (EXPIRE) Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislation as it relates to the renewable fuel standard.
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, FTI Government Affairs lobbied for Biotechnology Industry Organization , earning $80,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616762.xml
Lobbying Issues
Medicare Part B Drug Reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor Appropriations and Continuing Resolutions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislation as it relates to the renewable fuel standard.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, FTI Government Affairs lobbied for Biotechnology Industry Organization , earning $80,000. The report was filed on Oct. 21, 2013.
Original Filing: 300602964.xml
Lobbying Issues
Oppose Independent Payment Advisory Board (IPAB). Medicare Part B Drug Reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor Appropriations and Continuing Resolutions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislation as it relates to the renewable fuel standard.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, FTI Government Affairs lobbied for Biotechnology Industry Organization , earning $80,000. The report was filed on July 22, 2013.
Original Filing: 300583961.xml
Lobbying Issues
Oppose Independent Payment Advisory Board (IPAB). Medicare Part B Drug Reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor Appropriations and Continuing Resolutions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, FTI Government Affairs lobbied for Biotechnology Industry Organization , earning $10,000. The report was filed on April 19, 2013.
Original Filing: 300556472.xml
Lobbying Issues
Oppose Independent Payment Advisory Board (IPAB). Medicare Part B Drug Reimbursement.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitor Appropriations and Continuing Resolutions.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. S.3595, H.R.6559 to allow for certain high technology and biotechnology company to be eligible for Research and Development partnerships. S. 3232, a bill to extend and expand the Therapeutic Discovery Project Tax Credit Program. Advocate for improvements to the Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Amend and extend the Vaccine excise tax: S.3716; H.R. 6687. H.R. 475, Amend Vaccine Excise Tax.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
FTI Government Affairs filed a lobbying registration on April 18, 2013 to represent Biotechnology Industry Organization, effective March 15, 2013.
Original Filing: 300553294.xml
Issue(s) they said they’d lobby about: Oppose Independent Payment Advisory Board (IPAB). Medicare Part B Drug Reimbursement. Monitor Appropriations and Continuing Resolutions. Extend and expand Therapeutic Discovery Project (IRC 48D); capital formation tax policy; extend and expand R&D tax credit; monitor tax reform. Research and Development partnerships.Therapeutic Discovery Project Tax Credit Program. Internal Revenue Code Section 382 Net Operating Loss rules, Internal Revenue Code Section 1202 Small Business Capital gains rules and a more generous amortization period for Internal Revenue Code Section 197 intangibles. Vaccine excise tax. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...